The first experimental Ebola vaccine proved to be safe

Health and Natural Living. The Ebola virus is still a frightening disease. Until now there has been found to cure this disease. But recently there's latest research is the first experimental vaccine against Ebola disease that has been proven safe.

The first experiment Filovirus vaccine in Africa shows that such drugs produce the same immune response in adults healthy Uganda, as reported by American volunteers earlier this year.

It is expected that existing vaccine safety will help outbreaks still occur today in West Africa, which has claimed nearly 7,400 lives, as reported by the World Health Organization (WHO).

The DNA vaccine, which is designed to protect people from Ebola virus infection and related viruses such as Marburg. This virus has provided the basis for the development of more potent drugs to drugs that are currently being tested in the US, UK, Mali, and Uganda.

Author of the study, Dr. Julie Ledgerwood, of the National institues of Allergy and Infectious Desease (NIAID) and the National Institutes of Health said, that this is the first study to demonstrate the safety and immune response comparable experimental Ebola vaccine in Africa.

This is very encouraging because they are at risk of becoming infected with Ebola live mainly in Africa, and the protection of the vaccine in African populations also look for other diseases,

Scientists from the NIAID developed two DNA vaccines, which are taken from the Ebola virus proteins from strains of disease in Zaire and Sudan, as well as Marburg virus proteins. Immune response to this protein has been shown to be very protective of non-human primates.

Phase one trial conducted by Makerere University Walter Reed, involving 108 healthy adults aged between 18 and 50 years from Kampala, Uganda. The trial took place between November 2009 and April 2010.

Each volunteers were randomly assigned to injection, either vaccine Ebola, Marburg vaccine, and a combination of both, each of 30 volunteers. And placebo were given to 18 volunteers, at the beginning of the study. Then four and eight weeks later for the second time.

Four weeks after the third vaccination, more than half of the volunteers (17 of 30) had antibody responses to protein of Ebola Zaire as it did in 14 of the 30 participants who received the two vaccines, Ebola and Marburg.

However, antibodies that are not durable, back to undetectable levels within 11 months after vaccination.

Outbreaks of Ebola virus and Marburg virus infections have occurred sporadically since it was first detected in 1976 and 1967 respectively, and have a percentage of mortality reached respectively 90 percent and 80 percent.

Like the Ebola virus, Marburg is Filovirus which causes internal bleeding in a patient's body which can lead to death due to multiple organ failure. Until now, there has not been declared effective vaccine against the virus.